Thanks everyone for joining us this morning. I'm Drew Ranieri, one of the medical device analysts here at Morgan Stanley. It's my pleasure today to have Treace Medical with us. From the company, we have CEO John Treace, CFO Mark Hair, and Investor Relations Julie Dewey. Before we get started, just a brief disclaimer, but for important disclosures, see morganstanley.com/researchdisclosures. With that, let's kind of get into the discussion, and maybe first, let's talk about the market opportunity for Treace, John. You've mentioned that before that extremities is one of the faster-growing markets in orthopedics, growing high single digits. So a couple questions here. On the procedure side, you have about a 450,000 annual procedure opportunity. So maybe just talk about what you see in terms of that underlying market growth, and then how you're pulling patients off the sidelines who may not have been present before. Great, Drew, and thanks for having us. We're excited to be here at the Morgan Stanley conference. Yeah, talking about the market a little bit. So, foot and ankle is one of the fastest growing subsegments in orthopedics. And then the subsegment within that that we're playing in is the bunion and bunion-related product space, which we believe is the fastest growing subsegment of foot and ankle. So it's a great place to be. We've identified a market of about 1.1 million surgical candidates that we think are symptomatic, and that translates to about a $5 billion US opportunity TAM for us. That said, there are only about 450,000 patients being treated annually, and we think that's because of the deficiencies of the current standards of care, and that's what we're trying to change with Lapiplasty. So we're certainly targeting the existing 450,000 cases with our Lapiplasty procedure. But we are also, through our, our DTC patient awareness initiatives, getting the word out to patients that bunion surgery has changed, that there's a different procedure today, and they can learn about it at lapiplasty.com, our website. And they're going there, and they're learning more about their problem, and they're learning more about our procedure, and they're able to connect with doctors that do Lapiplasty on that site. So we believe we're tapping into both pieces, so we're having a good impact on the 450,000, but we know we're also reaching out to those that are higher up in the pipeline or sitting on the fence, waiting to get bunion surgery done because they've heard bad things about bunion surgery in the past. You know, it would not be uncommon to talk to somebody that's had bunion surgery and, and find out that half of those you talked to did not have a good experience, and they're not happy. We have dramatically different clinical outcomes with Lapiplasty and actual clinical data to back those claims, so we can take those messages to the patients, and that's been very helpful. Gotcha. Do you have a sense of maybe what kind of the core 450,000 procedures is growing at annually? Is it still high single digits or any other views, updated views on, on the growth rate? Yeah, well, the market reports would indicate somewhere in that low to mid single digit range. But beyond that, it's hard to ascertain exactly what that rate is. We hope that over time, we can help expand that rate of growth, you know, by our DTC efforts, our clinical data, our patient outreach, et cetera, so. Got it. Maybe just to quickly touch on GLP-1s, and we're asking most of our companies about this, but we've heard from orthopedic companies that the lower obesity could actually drive an acceleration in the market. But just any views, house views from Treace on what it could mean for bunion procedures, or if there's, like, a surgical threshold that some of these patients are unable to meet. Yeah, it's a great question, and we've spoken to a lot of our surgeon advisors about this because it's become such a popular topic. You know, bunions are a progressive deformity. They only get worse, and it's a deformity. It's not related to wear and tear on a joint. It's a pathology of the foot, the soft tissues and the bones, and they're genetic. They tend to run in families, so they don't really see a relationship between, you know, obesity and whether those patients are heavy or whether those patients are not heavy. So I don't think the GLP-1 is a factor in bunion surgery. Got it. Fair, fair. Maybe just to shift gears to some of the growth drivers in the business- Let's touch on kind of your procedure opportunity a bit more. But you've gained about 450 basis points of the market since 2018, and you're now about 6% penetrated in that kind of 450,000 opportunity. So maybe just talk to us about what the barriers are in kind of doubling your market penetration or maybe even just accelerating the penetration rate annually. Yeah, great question. You know, Drew, some of it is just a time factor because we've added about 42% of our surgeon users. 42% of our 2,600 surgeon users have come on in the past 24 months or sooner. So at that stage, they tend to be doing lower volumes. They're in that kind of 6-10 procedure range. We know that as they get out towards 5 years, they're approaching 20 procedures, so they ramp each year, they use Lapiplasty longer. So a lot of that is just time and getting those surgeons to run through the utilization curve. That said, you know, we think we've got a pretty powerful agenda in terms of trying to ramp utilization faster. That's adding more new sales reps that are focused on these customers and getting more surgeons on board, training them, and then gaining the business and gaining utilization. Second is launching new innovative products that make the procedure easier to do, quicker to do, less invasive for the patient and that will change their preference over time, more towards doing more Lapiplasty. Then third, you know, we got this powerful DTC initiative that's reaching out to patients, informing them about Lapiplasty. They can find the doctors online, they'll go into the practice asking about Lapiplasty, and if they're a candidate. Maybe just a little bit more on that. I think you've mentioned more recently that you think you could be a $600 million business one day, and that's penetration of 40% of the surgeon base, 20% procedure penetration, and that implies doubling your utilization to kind of reach that number. But outside of DTC, maybe medical education, kind of what are the other drivers and playbook that kind of gets you to a $600 million opportunity, even beyond? Yeah. So you're right. If we can get 40% of the 10,000 bunion surgeons using Lapiplasty and get them out to that 4-5-year time point on the curve, they're approaching that 20 procedures. With modest improvement in blended ASP throughout that timeframe, which is what we're doing through launching these complementary new products that go into the Lapiplasty case and build the wallet share per case. That's the other component that we think can, you know, help close that gap and narrow that gap over time. And maybe just on the blended ASP, kind of it's been growing maybe low single digits, mid single digits for, for a couple of years and even on a quarterly basis. Is that kind of how you're thinking about it in, in the model looking ahead? Is that a reasonable kind of rate that we should be kind of considering? Yeah, we've got a pretty nice pipeline lined up. You know, we affect blended ASP through two pathways. One, we're from time to time launching new and improved fixation systems, plating systems. Last year, we launched our S4A Plating System. That was very heavily embraced by the surgeon community and elevated our blended ASP on our core plating kits. Now we have SpeedPlate coming at the end of the year. That will be a premium price over S4A. So we're doing that with our underlying plating business, and that's providing some modest lift in the overall blended ASP number that we're recording. The other and more impactful piece are the launch of these new complementary products like we just announced last night, our hammertoe implant and our tissue release tools and osteotomes. These contribute meaningfully towards elevating the revenue per case. Those are the two contributors. So we grew blended ASP 13% in Q1, 8, 8% in Q2 over prior years. So, we feel pretty good about that mid-single-digit range. Got it. Maybe to go to active surgeons for a moment. Right now, you have 25% of the 10,000 surgeons in the US, and you've added slightly less than 200 surgeons first half this year, and we're modeling close to 500 for adds in 2023. Do you have any concerns that you kind of hit, like, the early phase of the adoption curve? And is it realistic to kind of expect 250-300 surgeons added looking ahead? It's just, it's a question that I've been getting more frequently from investors of just how to think about maybe the surgeon penetration and kind of like when that utilization kicks in, since you have, like, 40% of your surgeons are less than two years of experience or tenured on the product. Yeah, and Drew, maybe I'll jump in and provide a little commentary, and then maybe John can add a little bit more. So first of all, we've added already nearly 200 in the first half of this year, so we feel really good about all that opportunity and how many new surgeons continue to come to our medical education trainings. There's a lot of interest. We've got training throughout the country on a national, regional, and local level, so we feel good about that success. Another thing that we're doing right now, it's really in conjunction with what John was talking about, is not only are we training brand-new surgeons that have a lot of interest in Lapiplasty, but we've got this 2,600 surgeon count customers right now that we're also focused on to ensure that they are up to speed on all of our new technologies. So we've got an Adductoplasty, Mini-Incision System, a Micro system is coming out, SpeedPlate is coming out, the new Speed Release tools. So it's really a bifurcated focus to ensure that all of our existing surgeons are getting the training that they need to be great in the OR and to reduce that time in the OR, as well as bringing on new surgeons. With that said, seasonally, we typically have had more new customer surgeons come in the back half of the year. So we feel really good. That 250-300, we feel really good about that. For the back half? Well, saying on an annual basis to continue to add new surgeons. Looking out beyond 2023, that's a reasonable rate, and you're still on track to maybe hit the 500 this year? Well, we haven't given any specific guidance to a 500 count this year, but what we're saying on a go-forward basis, that 250-300, that seems definitely reasonable to us, given the interest that we continue to have and the seasonality that we see. Got it. And just with the active surgeon number that you give, it's a little difficult to, like, kind of see, like, how many of them have actually used the product before, and maybe stepped aside and re-engaging. But maybe just talk about the retention rate that you see for the surgeons. Can you discuss maybe what you're seeing, and just how you kind of close the gap to make sure that they are a repeat surgeon looking ahead? Yeah, great question. I'd say most of our surgeons are stick with it once they adopt. You know, not absolutely, but the majority do. A lot of ways that we can ensure that, you know, we're still aggressively expanding our direct sales force. That means we're putting a tighter ratio of doctors per rep in place. And when a rep has fewer doctors to call on and fewer doctors to service, they're gonna make sure that those doctors stick with the product, and they come to our advanced training events, and they embrace the new technologies that we put out that make the procedure better and better and better. So those are some of the ways that we can influence that number and influence that stickiness to Lapiplasty with the customer base. Just on the sales force side, the goal was to get to 200 by year-end. You did it by the second quarter. How should we be thinking about maybe incremental adds for the back half of the year? Really, like, kind of on your point about case coverage and being there to drive utilization, what's the ideal sales force size that you're thinking about to get to that $600 million revenue opportunity? Maybe your thoughts on, like, adding more, like, clinical support specialists to kind of aid there. Yeah, great question. We'll, we hit the 200, at the end of Q2. I will say that the vast majority of those 32 reps we added this year came at the very end of Q2. They came on at the very end of Q2. So we kind of anticipate, you know, they tend to ramp a little bit. In 6-9 months, they start making a little bit of an impact, but then they hit kind of full productivity out at the 2-year point. So we'll continue to selectively and opportunistically add on top of the 200 through the rest of the year, and then we'll figure out as we go into next year's planning, you know, line up how many we're going to need to deliver the objectives for next year and get that, the right, rep-to-surgeon count down to where we want it and achieve our growth objectives. Have you talked about kind of what that count looks like, rep-to-surgeon count, before publicly or any metrics? No. We've just given examples that, you know, if today we're at, call it 100 doctors to per rep, we're gonna keep whittling and whittling and whittling it down to get to that point where we know that optimum number of surgeons that provides great productivity and opportunity for the sales rep, but ensures that we're also getting, you know, tight coverage on all the doctors. Got it. In 2022 and even a bit of 2023 has been kind of the heavy investment year in the sales force. It sounds like it might be becoming a little bit more of an incremental versus a heavy investment looking ahead. Mm-hmm. Is that the right way to think about it, or could we see, like, kind of another influx of new direct reps coming? Yeah, I think that's a good way to couch it. We'll continue to, you know, first of all, we're gonna continue to advance our three initiatives that we mentioned when we started 2022. We wanted to invest aggressively in our direct sales channel. We wanted to invest in our R&D innovation pipeline. We're seeing the fruits of that come out right now and more to come. And then our DTC patient awareness. Those are the three areas. So definitely this year was a heavy lift. Next year, you know, we probably won't be, you know, doubling the sales force again, like we did last year, but we'll continue to make the right adds in those three areas to support our business plan. Got it. And on the rep productivity side, and we some more implant-based medtech companies, productivity rates, like $1.5 million-$2 million. How are you kind of thinking about that in terms of your model? I know you don't necessarily talk about kind of your model on the rep side, more on the surgeon side, but maybe, Mark, how do you kind of model this out in your projections when you're looking at sales force productivity? Yeah. So like you said, Drew, we often approach it from the surgeon count. We know the utilization that they have, and so we will continue to add our sales reps to ensure that we've got really good case coverage. We also find that as we are adding our new sales reps, that they continue to find new surgeons to bring them to our introductory med ed courses, and they begin their adoption process of our Lapiplasty system, and they move up that utilization curve that John referred to. So, you know, we're gonna continue to add sales reps. It's the gift that keeps on giving. It supports the surgeons in their cases, as well as bringing new surgeons. So we're gonna continue to add those sales reps over time. Thank you, and maybe on new products, some of the recent launches or recent approvals that came out this week. Maybe just talk about the opportunity for Micro- Lapiplasty, and maybe how you think that mix could evolve and kind of your core plating system and SpeedPlate, too and really both of these products influencing the blended ASP. Just give us a sense of maybe what the premium could be. Sure, sure. So SpeedPlate's pretty exciting because it does a few things for us. One, it appeals to a whole different group of surgeons that we're not doing business with today and serving today, that have a different philosophy on their hardware fixation. And these are surgeons that want compression. They like to use things like Nitinol staple technology, that you don't have to put in screws, and the implant compresses the joint. SpeedPlate offers the stability of a plate, but compression like a Nitinol staple, and that's a pretty attractive combination. So we see this as something that's going to generate more interest from surgeons we haven't had interest from in the past. Mm-hmm. A few things about it: It goes in very quickly, so it saves time in the case. It provides compression, and the surgeons who have been on the early evaluation have been raving about this product. I was at a meeting about three weeks ago, where a group of our early users were sharing their cases, and they were making comments like, "Second biggest launch from Treace Medical, ever. This is really meaningful technology." They were talking about the speed of the case. They were talking about the swelling that they're seeing, and they were talking about the rate of bone healing that they're seeing with this technology, and it was a pretty exciting discussion to hear. So as a standalone platform, SpeedPlate is fantastic. It's applicable to our Adductoplasty cases, it's applicable to all of our Lapiplasty cases, and it even has applications outside of, of those two procedures in foot and ankle. You'll have doctors, we think, that are going to be utilizing it in side cases for, for different indications, all on-label indications. But so that's a pretty exciting technology in itself. Micro- Lapiplasty relies on SpeedPlate because SpeedPlate was the only way we could make an implant small enough to put two in through a 2-centimeter incision. So Micro- Lapiplasty instrumentation, it's just another breakthrough from us, a 2-centimeter incision approach, Lapiplasty procedure enabled by SpeedPlate. We think it'll probably be embraced first by our most experienced surgeons, those that are more familiar with and utilize our Mini-Incision System today. They'll probably embrace this first, and then we'll continue to walk, you know, work our way through our base of surgeons and get it to the ultimate point of adoption. You know, a lot of these surgeons will use it as their go-to, we think, and then a lot will use it selectively. If a patient wants a smaller incision or they have some other reason for wanting to do very little tissue dissection. As with any, you know, surgical procedure that offers a smaller incision and less tissue trauma, you know, you tend to get less swelling and quicker recovery. And we see that as an opportunity with SpeedPlate and Micro. Maybe just follow up on SpeedPlate. You talked about some of the surgeons saying it's more efficient. You know, can you give a little bit more detail there? Is it possible to fit, like, another case, another couple cases in per day? Just maybe how are some of these more experienced users or even newer users for SpeedPlate thinking about it in their case loads? Yeah, great question. So today, our plate fixation, which is, which is fantastic because it provides 2 plating constructs, you know, 90 degrees apart, that provide this incredible stability so patients can bear weight early. That's been the big benefit of what we call Biplanar Plating. But to put them on, the surgeon has to place the plate, drill 8 holes for the 2 plates, and then put in 8 screws. With SpeedPlate, they just drill a few holes, and they pop the implant in because it's 1 piece. There's no screws there. It's a unibody construct. So if you can save, you know, 5-10 minutes on a Lapiplasty case and maybe 15 minutes or so on a Adductoplasty case, where you're putting in even more plates, that's really meaningful, and you're saving OR time, and the surgeons appreciate it. Yeah, it affords a lot of efficiency in the OR. Got it. And to follow up for the Micro- Lapiplasty, but talking to podiatrists and foot and ankle surgeons, and they're noticing in their practice that patients want, like, fewer incisions or smaller incisions, and there's been kind of a step change to more smaller products. But when you're thinking about Micro- Lapiplasty, do you think you're going to see more adoption from the mini Lapiplasty surgeons or kind of your core Lapiplasty docs in terms of just, like, a mix change? Yeah, great question. I think it. You know, that's where it comes into play. You know, for those surgeons that are really experienced and like the Mini-Incision System, and they're, they're almost competitive about it, I did a 2.5 or 3-centimeter Mini-Incision System procedure. You know, I think this is going to be very attractive to them, and this may overtake mini incisions. Throughout the broader user pool, you know, I think it would be adopted potentially by patient request or by those in the, in our surgeon pool that, that want to be cutting edge and want to be using the latest small incision technology on their patients. So we'll have to see how it's going to play out. It's early, but we're really excited about these two technologies. Got it. And you recently made an acquisition, RedPoint Medical. Maybe just talk about the integration process, and from an operation or even a technology standpoint, and maybe what the next milestones are that we should be looking at, product launches, anything there on the CT-based technology? Yeah, great question. We're really excited about RedPoint. You know, it fits so nicely with our forward initiative of making Lapiplasty and Adductoplasty faster, easier, less steps, more precise. To be able to take a patient's CT scan, generate an AI-enabled software model of a reconstruction or a correction through software, and then produce a cutting guide that is specialized with all the right cut angles, you know, for that patient, so the doctor can put the cut guide on, make their cuts, pull the bones together, and they're going to be in a fully corrected position. You know, that's a really, really exciting technology that has, you know, not only a lot of benefits for the surgeons and patients, but a lot of marketability around it, too. From where we are today, our engineers and our surgeon design team, they're integrating the technology with our core procedures. We may begin some cases here late in the year, early next year, and then we'll be refining it and looking for a launch in the bunion application, you know, a Lapiplasty type indication in the back half of next year and an Adductoplasty indication in the back half of next year as well. With this new technology, new enabling technology, are you approaching kind of your R&D differently than where you were before the acquisition? Well, you know, you need to create a new core capacity within the company. We're hiring software engineers now, you know, not mechanical and biomedical. We're adding to our team. So that's a great core competency that we're building inside the company that I think is going to serve us really well as we go through the next two, three, five years of evolution of our products. Now we have different ways of looking at it, you know, with RedPoint type of technology. Got it. Maybe just to pick on Mark for a little bit and give you a break. But with the back half numbers, I mean, one of the things that investors have asked is just kind of like what the deceleration is about and your guide for the third quarter implied for the fourth. Essentially, why not stronger than really where the guide is shaking out? I mean, you talked about adding, getting to the 200 reps by the end of the second quarter, so there might be some incremental help there. But maybe talk about your confidence in the back half and even some of the trends that you're seeing in the third quarter, given COVID spikes or seasonality or surgeon vacations. Yeah, great, great question, Drew. Appreciate that. And, you know, we don't comment on inter-quarter activities here that we have seen in the third quarter itself. But, you know, what we said earlier on our Q2 call was guidance of roughly equal revenue in Q3, plus or minus from what we saw in that activity in Q2, and that was really largely based on what we've talked about. Traditionally, Q3 is a little slower seasonally in orthopedics and elective procedures. And so we saw that in Q2, and we saw that as we started into Q3, and so that was really driving a lot of our commentary. And we've seen a protracted, really pent-up demand for some of these vacations and trips that both on the patient and surgeon side as well. We talked about that before as well. Now, with that said, we're seeing a lot of really strong interest in Lapiplasty through our DTC analytics, through a lot of our surgeon surveys, so we know that there's a lot of interest still. It's really a question of the timing of when patients are electing to have some of these procedures done. So we feel really good about all of these things that are happening here, all of our new product introductions that are driving increased utilization, increased interest for new surgeons coming in. And so we feel good about the back half of this year. Got it. And maybe heading into next year, I mean, the company's posted 50%+ growth on average. Guidance for this year is high 30s. I mean, how sustainable are these growth rates? I mean, you do have a large opportunity ahead of you, but does anything need to change, have to change in the playbook as you're going into 2024 and beyond? Mark, like, you can clean up on this one here. But, you know, I think we've got a great commercial plan, a great commercial strategy in place. We know the drivers of the top line. You know, we announced these four, I'm sorry, three new products, well, including SpeedPlate four last night, but inclusive of those, you know, we've got a pipeline over the next 12 months of eight new product introductions, and we talked about RedPoint, you know, following SpeedPlate. But then beyond that, we've got another platform that's quite significant that we believe is going to, you know, increase our opportunity to accelerate market penetration in the bunion space and utilization as well. You know, we feel like we've got a really good playbook in place that will allow us to continue to grow this company very nicely over the coming years. That should be like this time next year for that new product? Sometime in the back half of the year. Okay. Okay. We'll talk more about it later. And then maybe in the couple of minutes we have left, but back to Mark, just kind of a pathway to profitability. The company's hit net income profitability a couple of times in the fourth quarter with some of the leverage there. But your thoughts on EBITDA breakeven, could that be in 2025? Could it take longer? And just your views there. Yeah, great question. You know, we continue to have a focus on expense management, and we're benefiting from the increased scalability of the company as well. And so in Q2, we improved our Adjusted EBITDA 20% over the prior year, so we feel really good about all the efforts that we're making there. And fundamentally, in our company, as we continue to scale, as we continue to focus on driving, you know, new surgeons, the utilization, the increased blended ASP per case, we really feel that there's improved opportunities here. So we've talked about this year that we're gonna have some modest improvement on Adjusted EBITDA this year in both the dollar, as well as percentage basis over prior year. Fundamentally, Drew, you know, given what we're seeing here, you know, we don't really see any reason why we can't really meaningfully start approaching Adjusted EBITDA profitability, or breakeven, I should say, approaching that, breakeven, even into next year, 2024. So we'll have some nice improvements next year. We should expect, instead of it necessarily being a modest improvement, something maybe a little bit more meaningful for next year? Fundamentally, we don't see any reason why it, that couldn't be the case for next year. We feel really good about our trends, both from the top line as well as our expense management. Okay. Well, great. I appreciate the time. We'll have to wrap it there, but thank you, John, thank you, Mark, and Julie, for joining us today.